GlassScriptPhysician profile
Diane Spieker
NPI 1851356554
$291.24
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.99 · 2020: $11.88 · 2021: $35.69 · 2022: $15.22 · 2023: $82.17 · 2024: $69.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $151.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $82.75 | 2019-2024 | Paragard T 380a |
| Organon LLC | $57.20 | 2021-2023 | Nexplanon |
| Abbvie INC. | $53.27 | 2021-2023 | Liletta |
| Viiv Healthcare Company | $22.61 | 2023 | Apretude |
| Allergan, INC. | $18.67 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.21 | 2019 | |
| Minerva Surgical, INC | $16.79 | 2019 | |
| Avion Pharmaceuticals | $11.88 | 2020 | |
| Lupin INC. | $10.86 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Spieker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.